中国医院用药评价与分析2025，Vol.25Issue(11)：1303-1306,1311,5.DOI:10.14009/j.issn.1672-2124.2025.11.005
基于疾病风险校正的HV15病组用药分析及评价
Medication Analysis and Evaluation in HV15 DRG Group Based on Disease Risk Adjustment
摘要
Abstract
OBJECTIVE:Based on the disease risk adjustment model and disease diagnosis-related groups(DRG),through the cooperation and improvement mechanism of clinical pharmacists,clinicians,and specialized operation assistants,to evaluate,analyze,and propose optimization strategies for the drug consumption in the HV15 disease group(liver cirrhosis without significant complications and comorbidities).METHODS:Medication analysis and evaluation were conducted on 422 patients in the HV15 group of the hospital in 2024.Spearman rank correlation analysis was used to analyze the correlation between drug cost,length of stay,and hospitalization cost in HV15 group.Taking the hospital operation and evaluation as the goal and disease risk adjustment method as the core,on the basis of DRG,combined with the characteristics of medical cost structure in China,the O/E value[O/E value=actual occurrence value(O)/expected value(E)]was obtained,which could accurately locate to each patient and analyze the medication situation,and the evaluation and analysis path of the rationality of disease medication was established.RESULTS:The average hospitalization cost for the HV15 disease group was primarily composed of drug costs,with 26.07％of cases having an O/E value for drug costs greater than 1,indicating room for improvement.According to the Spearman correlation analysis,drug cost were positively correlated with length of stay and hospitalization cost.Further analysis and optimization were prioritized for patients in the HV15 disease group at the hospital in 2024,specifically those with a drug cost O/E greater than or equal to 1.5.Through drug use analysis,specific optimization measures were proposed for the top 1st,3rd,5th,and 6th ranked drugs in terms of drug cost for the disease type,including blood products,liver-protecting drugs,hepatitis antiviral drugs,and antibacterial drugs.CONCLUSIONS:Under the management of DRG,clinical pharmacists,clinicians and specialist operations assistants jointly promote the evaluation,review,and optimization of disease medication based on O/E value,which has reference value for reducing drug cost,hospitalization cost and shortening the length of stay.关键词
专科运营/肝硬化/HV15病组/用药分析/疾病风险校正/疾病诊断相关分组Key words
Specialized operation/Liver cirrhosis/HV15 group/Drug use analysis/Disease risk adjustment/Diagnosis-related groups分类
医药卫生引用本文复制引用
张森琳,吴诗叶,余云霓,游朋,李义平..基于疾病风险校正的HV15病组用药分析及评价[J].中国医院用药评价与分析,2025,25(11):1303-1306,1311,5.基金项目
国家卫健委医院管理研究所基于病种的标准化用耗研究课题(No.2025BH022) （No.2025BH022）
深圳市高水平医院建设专项经费资助(No.XKJS-2025041) （No.XKJS-2025041）
